Summary

KEY FINDINGS
The United States Alzheimer’s disease therapeutics & diagnostics market is expected to grow at a CAGR of 5.75% over the forecast period of 2024-2032. The market was valued at $2551.32 million in 2023 and is expected to reach a revenue of $4237.32 million by 2032.
MARKET INSIGHTS
The United States Alzheimer’s disease therapeutics & diagnostics industry is growing rapidly, escalated by increased investment in research and development, particularly in biomarkers for early dementia detection. These biomarkers are crucial for diagnosing Alzheimer’s at the earliest stages, allowing for timely intervention and more effective treatment options. As R&D progresses, the industry is poised to offer improved diagnostic tools and therapies, ultimately enhancing patient outcomes and slowing disease progression.
The demand for personalized medicine is also contributing to market growth. As healthcare shifts toward more individualized care, there is a growing focus on developing Alzheimer’s treatments tailored to each patient’s genetic makeup and health profile. Personalized therapies are expected to be more effective and have fewer side effects than traditional treatments, providing a better quality of care for Alzheimer’s patients.
The rise in Alzheimer’s disease cases is further fueling the market’s expansion. With the aging population, more individuals are reaching ages where Alzheimer’s and other neurodegenerative diseases are more prevalent. This demographic shift is increasing the need for both advanced diagnostics and effective treatments to manage the growing number of cases. Early detection, combined with innovative therapies, is essential to addressing the expanding burden of Alzheimer’s on patients and the healthcare system.
Moreover, advancements in diagnostic technologies are playing a critical role in the United States Alzheimer’s disease therapeutics & diagnostics market growth. Innovations like brain imaging and genetic testing are enhancing the ability to detect Alzheimer’s early, improving diagnostic accuracy and enabling healthcare providers to track disease progression more effectively. These technologies not only aid in earlier detection but also help in refining treatment plans, driving demand for more reliable and efficient diagnostic tools.
SEGMENTATION ANALYSIS
The United States Alzheimer’s disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further divided into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer’s disease, and other diagnostics).
The other diagnostics sub-segment in the market includes genetic testing, which identifies genetic predispositions to Alzheimer’s, enabling early intervention even before symptoms manifest. Another key diagnostic method is the use of blood-based biomarkers, which offer a non-invasive, cost-effective, and quicker alternative to traditional diagnostic tools. These diagnostics are crucial for detecting Alzheimer’s at its earliest stages, making it possible to implement more effective treatments.
Additionally, other diagnostics involve advanced cognitive and neuropsychological assessments, which help evaluate the extent of cognitive decline in patients. These assessments provide healthcare providers with valuable insights into the disease's progression. The combination of these diagnostic tools improves the ability to detect Alzheimer's early, increasing the chances of successful intervention. As research advances, new and improved diagnostic methods in this sub-segment will continue to play an integral role in shaping the future of Alzheimer’s care and treatment.
COMPETITIVE INSIGHTS
Some of the eminent companies operating in the United States Alzheimer’s disease therapeutics & diagnostics market include Johnson & Johnson, Eli Lilly and Company, F Hoffmann-La Roche AG, etc.
Johnson & Johnson, based in the United States, is a healthcare investment holding company involved in R&D, manufacturing, and marketing of personal care, pharmaceuticals, and surgical products. It operates through three main segments: Medical Devices, Pharmaceuticals, and Consumers. The Medical Devices segment offers a wide range of products for orthopedic, cancer, cardiovascular, surgery, neurology, infection prevention, and other medical needs, distributed to wholesalers, retailers, and healthcare providers.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GROWING R&D INVESTMENT IN THE BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.5.2. INCREASING DEMAND FOR THE PERSONALIZED MEDICINES
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS
3.2. KEY DRIVERS
3.2.1. INCREASE IN ALZHEIMER’S DISEASE CASES
3.2.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
3.2.3. GROWTH IN THE NUMBER OF DRUGS UNDER DEVELOPMENT
3.2.4. EXPANSION OF THE ELDERLY POPULATION
3.3. KEY RESTRAINTS
3.3.1. LIMITED AVAILABILITY OF SURROGATE MARKERS
3.3.2. LATE-STAGE DRUG FAILURES
3.3.3. STRICT GOVERNMENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
4.1.2. USAGE OF COMPUTED TOMOGRAPHY IN THE DIAGNOSTICS OF ALZHEIMER’S DISEASE
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. R&D
4.6.2. RAW MATERIAL
4.6.3. MANUFACTURING
4.6.4. WHOLESALERS/DISTRIBUTORS/RETAILERS
4.6.5. END-USER
4.7. KEY BUYING CRITERIA
4.7.1. PRICE
4.7.2. EFFICIENCY
4.7.3. SAFETY
4.8. ETYMOLOGY OF THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
4.9. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
5. MARKET BY PRODUCT
5.1. THERAPEUTICS
5.1.1. CHOLINESTERASE INHIBITORS
5.1.2. NMDA RECEPTOR ANTAGONISTS
5.1.3. OTHER THERAPEUTICS
5.2. DIAGNOSTICS
5.2.1. BRAIN IMAGING
5.2.2. CSF TEST FOR ALZHEIMER’S DISEASE
5.2.3. OTHER DIAGNOSTICS
6. COMPETITIVE LANDSCAPE
6.1. KEY STRATEGIC DEVELOPMENTS
6.1.1. MERGERS & ACQUISITIONS
6.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
6.1.3. PARTNERSHIPS & AGREEMENTS
6.1.4. BUSINESS EXPANSIONS & DIVESTITURES
6.2. COMPANY PROFILES
6.2.1. BIOGEN INC
6.2.1.1. COMPANY OVERVIEW
6.2.1.2. PRODUCT LIST
6.2.1.3. STRENGTHS & CHALLENGES
6.2.2. ELI LILLY AND COMPANY
6.2.2.1. COMPANY OVERVIEW
6.2.2.2. PRODUCT LIST
6.2.2.3. STRENGTHS & CHALLENGES
6.2.3. F HOFFMANN-LA ROCHE AG
6.2.3.1. COMPANY OVERVIEW
6.2.3.2. PRODUCT LIST
6.2.3.3. STRENGTHS & CHALLENGES
6.2.4. NOVARTIS AG
6.2.4.1. COMPANY OVERVIEW
6.2.4.2. PRODUCTS LIST
6.2.4.3. STRENGTHS & CHALLENGES
6.2.5. JOHNSON & JOHNSON
6.2.5.1. COMPANY OVERVIEW
6.2.5.2. PRODUCT LIST
6.2.5.3. STRENGTHS & CHALLENGES
6.2.6. MERCK & CO INC
6.2.6.1. COMPANY OVERVIEW
6.2.6.2. PRODUCT LIST
6.2.6.3. STRENGTHS & CHALLENGES
6.2.7. PFIZER INC
6.2.7.1. COMPANY OVERVIEW
6.2.7.2. PRODUCT LIST
6.2.7.3. STRENGTHS & CHALLENGES